{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emicizumab",
    "query": {
      "intervention": "Emicizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 37,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Emicizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T00:03:43.846Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04563520",
      "title": "SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "FEIBA",
          "type": "DRUG"
        },
        {
          "name": "rFVIIa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2026-09",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563520"
    },
    {
      "nct_id": "NCT04023019",
      "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Octanate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wilate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emicizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant factor VIIa (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated prothrombin complex concentrate (aPCC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023019"
    },
    {
      "nct_id": "NCT04205175",
      "title": "A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A With Inhibitor"
      ],
      "interventions": [
        {
          "name": "Feiba",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-01",
      "completion_date": "2022-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205175"
    },
    {
      "nct_id": "NCT05500807",
      "title": "Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Von Willebrand Disease, Type 3",
        "Concomitant VWD and Hemophilia"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bleeding and Clotting Disorders Institute Peoria, Illinois",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "0 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-11-01",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 12,
      "location_summary": "Orange, California • Redwood City, California • Coral Gables, Florida + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500807"
    },
    {
      "nct_id": "NCT07416604",
      "title": "A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "NXT007",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2026-04-27",
      "completion_date": "2032-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 6,
      "location_summary": "Orange, California • Aurora, Colorado • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07416604"
    },
    {
      "nct_id": "NCT05281718",
      "title": "Factor IX as Adjunctive Therapy to Emicizumab (EMIX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Factor IX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "12 Years to 120 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-01",
      "completion_date": "2024-07-14",
      "has_results": false,
      "last_update_posted_date": "2025-01-20",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 2,
      "location_summary": "Metairie, Louisiana • New Orleans, Louisiana",
      "locations": [
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05281718"
    },
    {
      "nct_id": "NCT04303559",
      "title": "The Hemophilia Inhibitor Prevention Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A Without Inhibitor"
      ],
      "interventions": [
        {
          "name": "Eloctate Injectable Product",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab Injection [Hemlibra]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "4 Years",
        "sex": "MALE",
        "summary": "4 Months to 4 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2021-10-11",
      "completion_date": "2022-06-16",
      "has_results": true,
      "last_update_posted_date": "2023-04-11",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 3,
      "location_summary": "Little Rock, Arkansas • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04303559"
    },
    {
      "nct_id": "NCT03921294",
      "title": "HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Haemophilic Pseudotumour"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana Hemophilia &Thrombosis Center, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1,
      "start_date": "2019-05-15",
      "completion_date": "2022-03-16",
      "has_results": true,
      "last_update_posted_date": "2024-04-11",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03921294"
    },
    {
      "nct_id": "NCT02847637",
      "title": "A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Emicizumab",
          "type": "DRUG"
        },
        {
          "name": "Factor VIII (FVIII)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2016-09-27",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 8,
      "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02847637"
    },
    {
      "nct_id": "NCT04621916",
      "title": "Preventing Inhibitor Recurrence Indefinitely",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hemophilia A",
        "Immune Tolerance"
      ],
      "interventions": [
        {
          "name": "FVIII",
          "type": "DRUG"
        },
        {
          "name": "Emicizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "12 Years",
        "sex": "MALE",
        "summary": "0 Years to 12 Years · Male only"
      },
      "enrollment_count": 52,
      "start_date": "2020-09-21",
      "completion_date": "2025-04-20",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-09-03T00:03:43.846Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04621916"
    }
  ]
}